![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Genotypic Characterisation of Filibuvir Resistance in Patients Receiving Four Weeks Co-administration of Filibuvir with pegIFN/RBV(12 Week Analysis)
|
|
|
Reported by Jules Levin
EASL Apr 14-18 2010 Vienna Austria
J Mori1, JL Hammond2, S Srinivasan2
S Jagannatha2, E Van der Ryst1
1Pfizer Global Research & Development, Sandwich, Kent, UK2Pfizer Global Research & Development, New London, CT, USA
![](../images/042710/042710-3/image002.gif)
![](../images/042710/042710-3/image004.gif)
![](../images/042710/042710-3/image006.gif)
![](../images/042710/042710-3/image008.gif)
![](../images/042710/042710-3/image010.gif)
Shi ST, et al. Antimicrob Agents Chemother2009;53:2544-2552
![](../images/042710/042710-3/image012.gif)
![](../images/042710/042710-3/image014.gif)
![](../images/042710/042710-3/image016.gif)
![](../images/042710/042710-3/image018.gif)
![](../images/042710/042710-3/image020.gif)
![](../images/042710/042710-3/image022.gif)
![](../images/042710/042710-3/image024.gif)
![](../images/042710/042710-3/image026.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|